Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Breast Cancer | Review

A promising target for breast cancer: B7-H3

Authors: Ying Jiang, Jiayu Liu, Lingyan Chen, Zhiwen Qian, Yan Zhang

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Breast cancer (BC) is the second-leading factor of mortality for women globally and is brought on by a variety of genetic and environmental causes. The conventional treatments for this disease have limitations, making it difficult to improve the lifespan of breast cancer patients. As a result, extensive research has been conducted over the past decade to find innovative solutions to these challenges. Targeting of the antitumor immune response through the immunomodulatory checkpoint protein B7 family has revolutionized cancer treatment and led to intermittent patient responses. B7-H3 has recently received attention because of its significant demodulation and its immunomodulatory effects in many cancers. Uncontrolled B7-H3 expression and a bad outlook are strongly associated, according to a substantial body of cancer research. Numerous studies have shown that BC has significant B7-H3 expression, and B7-H3 induces an immune evasion phenotype, consequently enhancing the survival, proliferation, metastasis, and drug resistance of BC cells. Thus, an innovative target for immunotherapy against BC may be the B7-H3 checkpoint.
In this review, we discuss the structure and regulation of B7-H3 and its double costimulatory/coinhibitory function within the framework of cancer and normal physiology. Then we expound the malignant behavior of B7-H3 in BC and its role in the tumor microenvironment (TME) and finally focus on targeted drugs against B7-H3 that have opened new therapeutic opportunities in BC.
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef
2.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22(8):1736–47.PubMedPubMedCentralCrossRef
3.
Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.PubMedCrossRef
4.
Hudis CA. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39–51.PubMedCrossRef
5.
6.
So JY, Ohm J, Lipkowitz S, Yang L. Triple negative breast cancer (TNBC): non-genetic tumor heterogeneity and immune microenvironment: emerging treatment options. Pharmacol Ther. 2022;237:108253.PubMedPubMedCentralCrossRef
7.
Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651–68.PubMedPubMedCentralCrossRef
8.
Bolandi N, Derakhshani A, Hemmat N, Baghbanzadeh A, Asadzadeh Z, Afrashteh Nour M, et al. The positive and negative immunoregulatory role of B7 family: promising novel targets in gastric cancer treatment. Int J Mol Sci. 2021;22(19):10719.PubMedPubMedCentralCrossRef
9.
Sadreddini S, Baradaran B, Aghebati-Maleki A, Sadreddini S, Shanehbandi D, Fotouhi A, et al. Immune checkpoint blockade opens a new way to cancer immunotherapy. J Cell Physiol. 2019;234(6):8541–9.PubMedCrossRef
10.
11.
Wang S, Bajorath J, Flies DB, Dong H, Honjo T, Chen L. Molecular modeling and functional mapping of B7–H1 and B7-DC uncouple costimulatory function from PD-1 interaction. J Exp Med. 2003;197(9):1083–91.PubMedPubMedCentralCrossRef
12.
Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7–H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800.PubMedCrossRef
13.
Hossain MA, Liu G, Dai B, Si Y, Yang Q, Wazir J, et al. Reinvigorating exhausted CD8(+) cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. Med Res Rev. 2021;41(1):156–201.PubMedCrossRef
14.
15.
Cai D, Li J, Liu D, Hong S, Qiao Q, Sun Q, et al. Tumor-expressed B7–H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy. Cell Mol Immunol. 2020;17(3):227–36.PubMedCrossRef
16.
Callahan MK, Postow MA, Wolchok JD. Targeting T Cell co-receptors for cancer therapy. Immunity. 2016;44(5):1069–78.PubMedCrossRef
17.
Pitt JM, Vétizou M, Daillère R, Roberti MP, Yamazaki T, Routy B, et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity. 2016;44(6):1255–69.PubMedCrossRef
18.
Kanchan RK, Perumal N, Atri P, Chirravuri Venkata R, Thapa I, Klinkebiel DL, et al. MiR-1253 exerts tumor-suppressive effects in medulloblastoma via inhibition of CDK6 and CD276 (B7–H3). Brain Pathol. 2020;30(4):732–45.PubMedPubMedCentralCrossRef
19.
Kanchan RK, Doss D, Khan P, Nasser MW, Mahapatra S. To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7–H3. Biochim Biophys Acta Rev Cancer. 2022;1877(5):188783.PubMedCrossRef
20.
Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, et al. Tumor cell and tumor vasculature expression of B7–H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res. 2008;14(16):5150–7.PubMedPubMedCentralCrossRef
21.
Getu AA, Tigabu A, Zhou M, Lu J, Fodstad Ø, Tan M. New frontiers in immune checkpoint B7–H3 (CD276) research and drug development. Mol Cancer. 2023;22(1):43.PubMedPubMedCentralCrossRef
22.
Chen H, Duan X, Deng X, Huang Y, Zhou X, Zhang S, et al. EBV-upregulated B7–H3 inhibits NK cell-mediated antitumor function and contributes to nasopharyngeal carcinoma progression. Cancer Immunol Res. 2023;11:830–46.PubMedCrossRef
23.
Wang C, Li Y, Jia L, Kim JK, Li J, Deng P, et al. CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance. Cell Stem Cell. 2021;28(9):1597-613.e7.PubMedPubMedCentralCrossRef
24.
25.
Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, et al. B7–H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A. 2007;104(49):19458–63.ADSPubMedPubMedCentralCrossRef
26.
Arigami T, Narita N, Mizuno R, Nguyen L, Ye X, Chung A, et al. B7–h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann Surg. 2010;252(6):1044–51.PubMedCrossRef
27.
Cong F, Yu H, Gao X. Expression of CD24 and B7–H3 in breast cancer and the clinical significance. Oncol Lett. 2017;14(6):7185–90.PubMedPubMedCentral
28.
Liu C, Liu J, Wang J, Liu Y, Zhang F, Lin W, et al. B7–H3 expression in ductal and lobular breast cancer and its association with IL-10. Mol Med Rep. 2013;7(1):134–8.PubMedCrossRef
29.
Pizon M, Schott DS, Pachmann U, Pachmann K. B7–H3 on circulating epithelial tumor cells correlates with the proliferation marker, Ki-67, and may be associated with the aggressiveness of tumors in breast cancer patients. Int J Oncol. 2018;53(5):2289–99.PubMed
30.
31.
Chen W, Liu P, Wang Y, Nie W, Li Z, Xu W, et al. Characterization of a soluble B7–H3 (sB7-H3) spliced from the intron and analysis of sB7-H3 in the sera of patients with hepatocellular carcinoma. PLoS One. 2013;8(10):e76965.ADSPubMedPubMedCentralCrossRef
32.
Zhang G, Hou J, Shi J, Yu G, Lu B, Zhang X. Soluble CD276 (B7–H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum. Immunology. 2008;123(4):538–46.PubMedPubMedCentralCrossRef
33.
Hwang JY, Jeong JM, Kwon MG, Seo JS, Hwang SD, Son MH, et al. Olive flounder CD276 (B7–H3) a coinhibitory molecule for T cells: responses during viral hemorrhagic septicemia virus (VHSV) stimulation. Fish Shellfish Immunol. 2018;73:228–33.PubMedCrossRef
34.
35.
Zhao B, Li H, Xia Y, Wang Y, Wang Y, Shi Y, et al. Immune checkpoint of B7–H3 in cancer: from immunology to clinical immunotherapy. J Hematol Oncol. 2022;15(1):153.PubMedPubMedCentralCrossRef
36.
Oh Y, Park R, Kim SY, Park SH, Jo S, Kim TH, et al. B7–H3 regulates osteoclast differentiation via type I interferon-dependent IDO induction. Cell Death Dis. 2021;12(11):971.PubMedPubMedCentralCrossRef
37.
Suh WK, Wang SX, Jheon AH, Moreno L, Yoshinaga SK, Ganss B, et al. The immune regulatory protein B7–H3 promotes osteoblast differentiation and bone mineralization. Proc Natl Acad Sci U S A. 2004;101(35):12969–73.ADSPubMedPubMedCentralCrossRef
38.
Picarda E, Galbo PM Jr, Zong H, Rajan MR, Wallenius V, Zheng D, et al. The immune checkpoint B7–H3 (CD276) regulates adipocyte progenitor metabolism and obesity development. Sci Adv. 2022;8(17):eabm7012.PubMedPubMedCentralCrossRef
39.
Flem-Karlsen K, Fodstad Ø, Nunes-Xavier CE. B7–H3 immune checkpoint protein in human cancer. Curr Med Chem. 2020;27(24):4062–86.PubMedCrossRef
40.
Flem-Karlsen K, Fodstad Ø, Tan M, Nunes-Xavier CE. B7–H3 in cancer - beyond immune regulation. Trends Cancer. 2018;4(6):401–4.PubMedCrossRef
41.
42.
Picarda E, Ohaegbulam KC, Zang X. Molecular pathways: targeting B7–H3 (CD276) for human cancer immunotherapy. Clin Cancer Res. 2016;22(14):3425–31.PubMedPubMedCentralCrossRef
43.
Nygren MK, Tekle C, Ingebrigtsen VA, Mäkelä R, Krohn M, Aure MR, et al. Identifying microRNAs regulating B7–H3 in breast cancer: the clinical impact of microRNA-29c. Br J Cancer. 2014;110(8):2072–80.PubMedPubMedCentralCrossRef
44.
45.
Avci O, Çavdar E, İriağaç Y, Karaboyun K, Çelikkol A, Özçağlayan TİK, et al. Soluble B7H3 level in breast cancer and its relationship with clinicopathological variables and T cell infiltration. Contemp Oncol (Pozn). 2022;26(1):27–31.PubMed
46.
Dube DH, Bertozzi CR. Glycans in cancer and inflammation–potential for therapeutics and diagnostics. Nat Rev Drug Discov. 2005;4(6):477–88.PubMedCrossRef
47.
Huang Y, Zhang HL, Li ZL, Du T, Chen YH, Wang Y, et al. FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer. Nat Commun. 2021;12(1):2672.ADSPubMedPubMedCentralCrossRef
48.
Dittmer J. Breast cancer stem cells: features, key drivers and treatment options. Semin Cancer Biol. 2018;53:59–74.PubMedCrossRef
49.
Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell. 2011;146(4):633–44.PubMedCrossRef
50.
Atashzar MR, Baharlou R, Karami J, Abdollahi H, Rezaei R, Pourramezan F, et al. Cancer stem cells: a review from origin to therapeutic implications. J Cell Physiol. 2020;235(2):790–803.PubMedCrossRef
51.
52.
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983–8.ADSPubMedPubMedCentralCrossRef
53.
Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555–67.PubMedPubMedCentralCrossRef
54.
Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006;98(24):1777–85.PubMedCrossRef
55.
56.
57.
Liu Z, Zhang W, Phillips JB, Arora R, McClellan S, Li J, et al. Immunoregulatory protein B7–H3 regulates cancer stem cell enrichment and drug resistance through MVP-mediated MEK activation. Oncogene. 2019;38(1):88–102.PubMedCrossRef
58.
Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S, et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell. 2014;25(5):697–710.PubMedPubMedCentralCrossRef
59.
Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–75.PubMedPubMedCentralCrossRef
60.
61.
62.
63.
Xiong Z, Deng G, Huang X, Li X, Xie X, Wang J, et al. Bone metastasis pattern in initial metastatic breast cancer: a population-based study. Cancer Manag Res. 2018;10:287–95.PubMedPubMedCentralCrossRef
64.
Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68(9):3108–14.PubMedCrossRef
65.
Pentheroudakis G, Fountzilas G, Bafaloukos D, Koutsoukou V, Pectasides D, Skarlos D, et al. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast Cancer Res Treat. 2006;97(3):237–44.PubMedCrossRef
66.
67.
Wang Y, Ye F, Liang Y, Yang Q. Breast cancer brain metastasis: insight into molecular mechanisms and therapeutic strategies. Br J Cancer. 2021;125(8):1056–67.PubMedPubMedCentralCrossRef
68.
Yu TT, Zhang T, Lu X, Wang RZ. B7–H3 promotes metastasis, proliferation, and epithelial-mesenchymal transition in lung adenocarcinoma. Onco Targets Ther. 2018;11:4693–700.PubMedPubMedCentralCrossRef
69.
Castellanos JR, Purvis IJ, Labak CM, Guda MR, Tsung AJ, Velpula KK, et al. B7–H3 role in the immune landscape of cancer. Am J Clin Exp Immunol. 2017;6(4):66–75.PubMedPubMedCentral
70.
Tekle C, Nygren MK, Chen YW, Dybsjord I, Nesland JM, Maelandsmo GM, et al. B7–H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes. Int J Cancer. 2012;130(10):2282–90.PubMedCrossRef
71.
Wang L, Zhang Q, Chen W, Shan B, Ding Y, Zhang G, et al. B7–H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis. PLoS One. 2013;8(8):e70689.ADSPubMedPubMedCentralCrossRef
72.
Liu F, Zhang T, Zou S, Jiang B, Hua D. B7–H3 promotes cell migration and invasion through the Jak2/Stat3/MMP9 signaling pathway in colorectal cancer. Mol Med Rep. 2015;12(4):5455–60.PubMedCrossRef
73.
Liao H, Ding M, Zhou N, Yang Y, Chen L. B7–H3 promotes the epithelial-mesenchymal transition of NSCLC by targeting SIRT1 through the PI3K/AKT pathway. Mol Med Rep. 2022;25(3):79.PubMedPubMedCentralCrossRef
74.
Xie J, Sun M, Zhang D, Chen C, Lin S, Zhang G. Fibronectin enhances tumor metastasis through B7–H3 in clear cell renal cell carcinoma. FEBS Open Bio. 2021;11(11):2977–87.PubMedPubMedCentralCrossRef
75.
Xie C, Liu D, Chen Q, Yang C, Wang B, Wu H. Soluble B7–H3 promotes the invasion and metastasis of pancreatic carcinoma cells through the TLR4/NF-κB pathway. Sci Rep. 2016;6:27528.ADSPubMedPubMedCentralCrossRef
76.
77.
Li L, Liang Y, Kang L, Liu Y, Gao S, Chen S, et al. Transcriptional regulation of the Warburg effect in cancer by SIX1. Cancer Cell. 2018;33(3):368-85.e7.PubMedCrossRef
78.
Wang Y, Tahiri H, Yang C, Gu M, Ruan X, Hardy P. Overexpression of miR-181a regulates the Warburg effect in triple-negative breast cancer. Climacteric. 2023;26(1):64–71.PubMedCrossRef
79.
Jiang H, Wei H, Wang H, Wang Z, Li J, Ou Y, et al. Zeb1-induced metabolic reprogramming of glycolysis is essential for macrophage polarization in breast cancer. Cell Death Dis. 2022;13(3):206.PubMedPubMedCentralCrossRef
80.
Li J, Qu P, Zhou XZ, Ji YX, Yuan S, Liu SP, et al. Pimozide inhibits the growth of breast cancer cells by alleviating the Warburg effect through the P53 signaling pathway. Biomed Pharmacother. 2022;150:113063.PubMedCrossRef
81.
Wu H, Jiao Y, Zhou C, Guo X, Wu Z, Lv Q. miR-140-3p/usp36 axis mediates ubiquitination to regulate PKM2 and suppressed the malignant biological behavior of breast cancer through Warburg effect. Cell Cycle. 2023;22(6):680–92.PubMedCrossRef
82.
Zhang X, Luo F, Luo S, Li L, Ren X, Lin J, et al. Transcriptional repression of aerobic glycolysis by OVOL2 in breast cancer. Adv Sci (Weinh). 2022;9(27):e2200705.PubMedCrossRef
83.
Lim S, Liu H, Madeira da Silva L, Arora R, Liu Z, Phillips JB, et al. Immunoregulatory protein B7–H3 reprograms glucose metabolism in cancer cells by ROS-mediated stabilization of HIF1α. Cancer Res. 2016;76(8):2231–42.PubMedPubMedCentralCrossRef
84.
Nunes-Xavier CE, Karlsen KF, Tekle C, Pedersen C, Øyjord T, Hongisto V, et al. Decreased expression of B7–H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors. Oncotarget. 2016;7(6):6891–901.PubMedPubMedCentralCrossRef
85.
Liu J, Yang S, Cao B, Zhou G, Zhang F, Wang Y, et al. Targeting B7–H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. J Hematol Oncol. 2021;14(1):21.PubMedPubMedCentralCrossRef
86.
Abad E, Graifer D, Lyakhovich A. DNA damage response and resistance of cancer stem cells. Cancer Lett. 2020;474:106–17.PubMedCrossRef
87.
Raman D, Cimpean AM, De Miglio MR. Editorial: drug resistance in breast cancer - mechanisms and approaches to overcome chemoresistance. Front Oncol. 2022;12:1080684.PubMedCrossRef
88.
Brown KA, Andreopoulou E, Andreopoulou P. Endocrine therapy-related endocrinopathies-biology, prevalence and implications for the management of breast cancer. Oncol Hematol Rev. 2020;16(1):17–22.PubMedPubMedCentral
89.
Beyaz H, Uludag H, Kavaz D, Rizaner N. Mechanisms of drug resistance and use of nanoparticle delivery to overcome resistance in breast cancers. Adv Exp Med Biol. 2021;1347:163–81.PubMedCrossRef
90.
Zhang P, Chen Z, Ning K, Jin J, Han X. Inhibition of B7–H3 reverses oxaliplatin resistance in human colorectal cancer cells. Biochem Biophys Res Commun. 2017;490(3):1132–8.PubMedCrossRef
91.
Pulido R, Nunes-Xavier CE. Hopes on immunotherapy targeting B7–H3 in neuroblastoma. Transl Oncol. 2023;27:101580.PubMedCrossRef
92.
Fan R, Chen C, Hu J, Mu M, Chuan D, Chen Z, et al. Multifunctional gold nanorods in low-temperature photothermal interactions for combined tumor starvation and RNA interference therapy. Acta Biomater. 2023;159:324–37.PubMedCrossRef
93.
Nunes-Xavier CE, Emaldi M, Guldvik IJ, Ramberg H, Taskén KA, Mælandsmo GM, et al. Correlation of expression of Major Vault Protein with androgen receptor and immune checkpoint protein B7–H3, and with poor prognosis in prostate cancer. Pathol Res Pract. 2023;241:154243.PubMedCrossRef
94.
Guo C, Figueiredo I, Gurel B, Neeb A, Seed G, Crespo M, et al. B7–H3 as a therapeutic target in advanced prostate cancer. Eur Urol. 2023;83(3):224–38.PubMedCrossRef
95.
Mahmoud AM, Frank I, Orme JJ, Lavoie RR, Thapa P, Costello BA, et al. Evaluation of PD-L1 and B7–H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer. BMC Urol. 2022;22(1):90.PubMedPubMedCentralCrossRef
96.
Liu H, Tekle C, Chen YW, Kristian A, Zhao Y, Zhou M, et al. B7–H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation. Mol Cancer Ther. 2011;10(6):960–71.PubMedPubMedCentralCrossRef
97.
98.
99.
Jiménez-Martínez M, Stamatakis K, Fresno M. The Dual-Specificity Phosphatase 10 (DUSP10): its role in cancer, inflammation, and immunity. Int J Mol Sci. 2019;20(7):1626.PubMedPubMedCentralCrossRef
100.
Flem-Karlsen K, Tekle C, Øyjord T, Flørenes VA, Mælandsmo GM, Fodstad Ø, et al. p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance. Sci Rep. 2019;9(1):5839.ADSPubMedPubMedCentralCrossRef
101.
Cánovas B, Igea A, Sartori AA, Gomis RR, Paull TT, Isoda M, et al. Targeting p38α increases DNA damage, chromosome instability, and the anti-tumoral response to taxanes in breast cancer cells. Cancer Cell. 2018;33(6):1094-110.e8.PubMedCrossRef
102.
103.
Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, et al. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol. 2021;14(1):156.PubMedPubMedCentralCrossRef
104.
105.
106.
Groth C, Hu X, Weber R, Fleming V, Altevogt P, Utikal J, et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer. 2019;120(1):16–25.PubMedCrossRef
107.
108.
109.
Tannenbaum CS, Rayman PA, Pavicic PG, Kim JS, Wei W, Polefko A, et al. Mediators of inflammation-driven expansion, trafficking, and function of tumor-infiltrating MDSCs. Cancer Immunol Res. 2019;7(10):1687–99.PubMedPubMedCentralCrossRef
110.
111.
Casbon AJ, Reynaud D, Park C, Khuc E, Gan DD, Schepers K, et al. Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proc Natl Acad Sci U S A. 2015;112(6):E566–75.PubMedPubMedCentralCrossRef
112.
Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58(1):49–59.PubMedCrossRef
113.
Yu J, Wang Y, Yan F, Li H, Ren X. Response to comment on “Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer.” J Immunol. 2013;190(11):5341–2.PubMedCrossRef
114.
Li W, Tanikawa T, Kryczek I, Xia H, Li G, Wu K, et al. Aerobic glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific CEBPB isoform in triple-negative breast cancer. Cell Metab. 2018;28(1):87-103.e6.PubMedPubMedCentralCrossRef
115.
Zhang G, Huang H, Zhu Y, Yu G, Gao X, Xu Y, et al. A novel subset of B7–H3(+)CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells are associated with progression of human NSCLC. Oncoimmunology. 2015;4(2):e977164.PubMedPubMedCentralCrossRef
116.
Liu T, Gonzalez De Los Santos F, Rinke AE, Fang C, Flaherty KR, Phan SH. B7H3-dependent myeloid-derived suppressor cell recruitment and activation in pulmonary fibrosis. Front Immunol. 2022;13:901349.PubMedPubMedCentralCrossRef
117.
Fang C, Rinke AE, Wang J, Flaherty KR, Phan SH, Liu T. B7H3 expression and significance in idiopathic pulmonary fibrosis. J Pathol. 2022;256(3):310–20.PubMedCrossRef
118.
Lee YH, Martin-Orozco N, Zheng P, Li J, Zhang P, Tan H, et al. Inhibition of the B7–H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Res. 2017;27(8):1034–45.PubMedPubMedCentralCrossRef
119.
120.
Cassetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell. 2019;35(4):588-602.e10.PubMedPubMedCentralCrossRef
121.
Li H, Yang P, Wang J, Zhang J, Ma Q, Jiang Y, et al. HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk. J Hematol Oncol. 2022;15(1):2.PubMedPubMedCentralCrossRef
122.
Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124(2):263–6.PubMedCrossRef
123.
Goswami S, Sahai E, Wyckoff JB, Cammer M, Cox D, Pixley FJ, et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res. 2005;65(12):5278–83.PubMedCrossRef
124.
Coniglio SJ, Eugenin E, Dobrenis K, Stanley ER, West BL, Symons MH, et al. Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol Med. 2012;18(1):519–27.PubMedPubMedCentralCrossRef
125.
126.
Mao Y, Chen L, Wang F, Zhu D, Ge X, Hua D, et al. Cancer cell-expressed B7–H3 regulates the differentiation of tumor-associated macrophages in human colorectal carcinoma. Oncol Lett. 2017;14(5):6177–83.PubMedPubMedCentral
127.
Miyamoto T, Murakami R, Hamanishi J, Tanigaki K, Hosoe Y, Mise N, et al. B7–H3 suppresses antitumor immunity via the CCL2-CCR2-M2 macrophage axis and contributes to ovarian cancer progression. Cancer Immunol Res. 2022;10(1):56–69.PubMedCrossRef
128.
Cheng N, Bei Y, Song Y, Zhang W, Xu L, Zhang W, et al. B7–H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy. Biochem Pharmacol. 2021;183:114298.PubMedCrossRef
129.
Gao Y, Fang P, Li WJ, Zhang J, Wang GP, Jiang DF, et al. LncRNA NEAT1 sponges miR-214 to regulate M2 macrophage polarization by regulation of B7–H3 in multiple myeloma. Mol Immunol. 2020;117:20–8.PubMedCrossRef
130.
Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15(7):405–14.PubMedCrossRef
131.
Tan AH, Goh SY, Wong SC, Lam KP. T helper cell-specific regulation of inducible costimulator expression via distinct mechanisms mediated by T-bet and GATA-3. J Biol Chem. 2008;283(1):128–36.PubMedCrossRef
132.
Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009;27(35):5944–51.PubMedCrossRef
133.
Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008;26(27):4410–7.PubMedCrossRef
134.
Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2012;124(2):192–8.PubMedCrossRef
135.
Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105–13.PubMedCrossRef
136.
Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin Oncol. 2013;31(7):860–7.PubMedCrossRef
137.
Adams S, Gatti-Mays ME, Kalinsky K, Korde LA, Sharon E, Amiri-Kordestani L, et al. Current landscape of immunotherapy in breast cancer: a review. JAMA Oncol. 2019;5(8):1205–14.PubMedPubMedCentralCrossRef
138.
Monnot GC, Romero P. Rationale for immunological approaches to breast cancer therapy. Breast. 2018;37:187–95.PubMedCrossRef
139.
Dieci MV, Mathieu MC, Guarneri V, Conte P, Delaloge S, Andre F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol. 2015;26(8):1698–704.PubMedPubMedCentralCrossRef
140.
Zhou XY, Yashiro-Ohtani Y, Nakahira M, Park WR, Abe R, Hamaoka T, et al. Molecular mechanisms underlying differential contribution of CD28 versus non-CD28 costimulatory molecules to IL-2 promoter activation. J Immunol. 2002;168(8):3847–54.PubMedCrossRef
141.
Jain J, Loh C, Rao A. Transcriptional regulation of the IL-2 gene. Curr Opin Immunol. 1995;7(3):333–42.PubMedCrossRef
142.
Quintana Á, Peg V, Prat A, Moliné T, Villacampa G, Paré L, et al. Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. Eur J Cancer. 2021;148:134–45.PubMedCrossRef
143.
Ignatiadis M, Van den Eynden G, Roberto S, Fornili M, Bareche Y, Desmedt C, et al. Tumor-infiltrating lymphocytes in patients receiving trastuzumab/pertuzumab-based chemotherapy: A TRYPHAENA substudy. J Natl Cancer Inst. 2019;111(1):69–77.PubMedCrossRef
144.
145.
Göschl L, Scheinecker C, Bonelli M. Treg cells in autoimmunity: from identification to Treg-based therapies. Semin Immunopathol. 2019;41(3):301–14.PubMedCrossRef
146.
147.
Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6(4):295–307.PubMedCrossRef
148.
de la Cruz-Merino L, Chiesa M, Caballero R, Rojo F, Palazón N, Carrasco FH, et al. Breast cancer immunology and immunotherapy: current status and future perspectives. Int Rev Cell Mol Biol. 2017;331:1–53.PubMedCrossRef
149.
Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C, Prabhakaran S, et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell. 2018;174(5):1293-308.e36.PubMedPubMedCentralCrossRef
150.
De Simone M, Arrigoni A, Rossetti G, Gruarin P, Ranzani V, Politano C, et al. Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells. Immunity. 2016;45(5):1135–47.PubMedPubMedCentralCrossRef
151.
Qiu J, Xu L, Zeng X, Wu H, Liang F, Lv Q, et al. CCL5 mediates breast cancer metastasis and prognosis through CCR5/Treg cells. Front Oncol. 2022;12:972383.PubMedPubMedCentralCrossRef
152.
Iida K, Miyake M, Onishi K, Hori S, Morizawa Y, Gotoh D, et al. Prognostic impact of tumor-infiltrating CD276/Foxp3-positive lymphocytes and associated circulating cytokines in patients undergoing radical nephrectomy for localized renal cell carcinoma. Oncol Lett. 2019;17(4):4004–10.PubMedPubMedCentral
153.
Zheng Y, Josefowicz SZ, Kas A, Chu TT, Gavin MA, Rudensky AY. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature. 2007;445(7130):936–40.ADSPubMedCrossRef
154.
Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA, et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature. 2007;445(7129):771–5.ADSPubMedCrossRef
155.
Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4(4):330–6.PubMedCrossRef
156.
Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057–61.ADSPubMedCrossRef
157.
Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol. 2003;4(4):337–42.PubMedCrossRef
158.
Jin Y, Zhang P, Li J, Zhao J, Liu C, Yang F, et al. B7–H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer. Int J Clin Exp Pathol. 2015;8(11):13987–95.PubMedPubMedCentral
159.
Dotto GP, Weinberg RA, Ariza A. Malignant transformation of mouse primary keratinocytes by Harvey sarcoma virus and its modulation by surrounding normal cells. Proc Natl Acad Sci U S A. 1988;85(17):6389–93.ADSPubMedPubMedCentralCrossRef
160.
Costa A, Scholer-Dahirel A, Mechta-Grigoriou F. The role of reactive oxygen species and metabolism on cancer cells and their microenvironment. Semin Cancer Biol. 2014;25:23–32.PubMedCrossRef
161.
162.
Gentric G, Mieulet V, Mechta-Grigoriou F. Heterogeneity in cancer metabolism: new concepts in an old field. Antioxid Redox Signal. 2017;26(9):462–85.PubMedPubMedCentralCrossRef
163.
Öhlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579–96.PubMedPubMedCentralCrossRef
164.
Sugimoto H, Mundel TM, Kieran MW, Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther. 2006;5(12):1640–6.PubMedCrossRef
165.
166.
Lee HW, Park YM, Lee SJ, Cho HJ, Kim DH, Lee JI, et al. Alpha-smooth muscle actin (ACTA2) is required for metastatic potential of human lung adenocarcinoma. Clin Cancer Res. 2013;19(21):5879–89.PubMedCrossRef
167.
Parajuli H, Teh MT, Abrahamsen S, Christoffersen I, Neppelberg E, Lybak S, et al. Integrin α11 is overexpressed by tumour stroma of head and neck squamous cell carcinoma and correlates positively with alpha smooth muscle actin expression. J Oral Pathol Med. 2017;46(4):267–75.PubMedCrossRef
168.
Toullec A, Gerald D, Despouy G, Bourachot B, Cardon M, Lefort S, et al. Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol Med. 2010;2(6):211–30.PubMedPubMedCentralCrossRef
169.
170.
Guise TA. Breast cancer bone metastases: it’s all about the neighborhood. Cell. 2013;154(5):957–9.PubMedCrossRef
171.
Zhang XH, Jin X, Malladi S, Zou Y, Wen YH, Brogi E, et al. Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell. 2013;154(5):1060–73.PubMedPubMedCentralCrossRef
172.
Zhang S, Zhou C, Zhang D, Huang Z, Zhang G. The anti-apoptotic effect on cancer-associated fibroblasts of B7–H3 molecule enhancing the cell invasion and metastasis in renal cancer. Onco Targets Ther. 2019;12:4119–27.PubMedPubMedCentralCrossRef
173.
Zhan S, Liu Z, Zhang M, Guo T, Quan Q, Huang L, et al. Overexpression of B7–H3 in α-SMA-positive fibroblasts is associated with cancer progression and survival in gastric adenocarcinomas. Front Oncol. 2019;9:1466.PubMedCrossRef
174.
Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell. 2018;33(3):463-79.e10.PubMedCrossRef
175.
Souweidane MM, Kramer K, Pandit-Taskar N, Zhou Z, Haque S, Zanzonico P, et al. Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. Lancet Oncol. 2018;19(8):1040–50.PubMedPubMedCentralCrossRef
176.
Lu H, Shi T, Wang M, Li X, Gu Y, Zhang X, et al. B7–H3 inhibits the IFN-γ-dependent cytotoxicity of Vγ9Vδ2 T cells against colon cancer cells. Oncoimmunology. 2020;9(1):1748991.PubMedPubMedCentralCrossRef
177.
Modak S, Kramer K, Gultekin SH, Guo HF, Cheung NK. Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res. 2001;61(10):4048–54.PubMed
178.
Kramer K, Kushner BH, Modak S, Pandit-Taskar N, Smith-Jones P, Zanzonico P, et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol. 2010;97(3):409–18.PubMedCrossRef
179.
Kohrt HE, Houot R, Marabelle A, Cho HJ, Osman K, Goldstein M, et al. Combination strategies to enhance antitumor ADCC. Immunotherapy. 2012;4(5):511–27.PubMedCrossRef
180.
Loo D, Alderson RF, Chen FZ, Huang L, Zhang W, Gorlatov S, et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res. 2012;18(14):3834–45.PubMedCrossRef
181.
Nisonoff A, Wissler FC, Lipman LN. Properties of the major component of a peptic digest of rabbit antibody. Science. 1960;132(3441):1770–1.ADSPubMedCrossRef
182.
Labrijn AF, Janmaat ML, Reichert JM, Parren P. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585–608.PubMedCrossRef
183.
Ma J, Ma P, Zhao C, Xue X, Han H, Liu C, et al. B7–H3 as a promising target for cytotoxicity T cell in human cancer therapy. Oncotarget. 2016;7(20):29480–91.PubMedPubMedCentralCrossRef
184.
Huang C, Duan X, Wang J, Tian Q, Ren Y, Chen K, et al. Lipid nanoparticle delivery system for mRNA encoding B7H3-redirected bispecific antibody displays potent antitumor effects on malignant tumors. Adv Sci (Weinh). 2023;10(3):e2205532.PubMedCrossRef
185.
Bouchard H, Viskov C, Garcia-Echeverria C. Antibody-drug conjugates—a new wave of cancer drugs. Bioorg Med Chem Lett. 2014;24(23):5357–63.PubMedCrossRef
186.
187.
Scribner JA, Brown JG, Son T, Chiechi M, Li P, Sharma S, et al. Preclinical development of MGC018, a Duocarmycin-based antibody-drug conjugate targeting B7–H3 for solid cancer. Mol Cancer Ther. 2020;19(11):2235–44.PubMedCrossRef
188.
189.
Cai L, Michelakos T, Yamada T, Fan S, Wang X, Schwab JH, et al. Defective HLA class I antigen processing machinery in cancer. Cancer Immunol Immunother. 2018;67(6):999–1009.PubMedPubMedCentralCrossRef
190.
Tang X, Zhao S, Zhang Y, Wang Y, Zhang Z, Yang M, et al. B7–H3 as a novel CAR-T therapeutic target for glioblastoma. Mol Ther Oncolytics. 2019;14:279–87.PubMedPubMedCentralCrossRef
191.
Nehama D, Di Ianni N, Musio S, Du H, Patané M, Pollo B, et al. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. EBioMedicine. 2019;47:33–43.PubMedPubMedCentralCrossRef
192.
Zhang Z, Jiang C, Liu Z, Yang M, Tang X, Wang Y, et al. B7-H3-targeted CAR-T cells exhibit potent antitumor effects on hematologic and solid tumors. Mol Ther Oncolytics. 2020;17:180–9.PubMedPubMedCentralCrossRef
193.
Zheng M, Yu L, Hu J, Zhang Z, Wang H, Lu D, et al. Efficacy of B7-H3-redirected BiTE and CAR-T immunotherapies against extranodal nasal natural killer/T cell lymphoma. Transl Oncol. 2020;13(5):100770.PubMedPubMedCentralCrossRef
194.
Tang X, Liu F, Liu Z, Cao Y, Zhang Z, Wang Y, et al. Bioactivity and safety of B7-H3-targeted chimeric antigen receptor T cells against anaplastic meningioma. Clin Transl Immunol. 2020;9(6): e1137.CrossRef
195.
Pierce S, Geanes ES, Bradley T. Targeting natural killer cells for improved immunity and control of the adaptive immune response. Front Cell Infect Microbiol. 2020;10:231.PubMedPubMedCentralCrossRef
196.
Burger MC, Zhang C, Harter PN, Romanski A, Strassheimer F, Senft C, et al. CAR-engineered NK cells for the treatment of glioblastoma: turning innate effectors into precision tools for cancer immunotherapy. Front Immunol. 2019;10:2683.PubMedPubMedCentralCrossRef
197.
Chou CK, Turtle CJ. Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy. Bone Marrow Transplant. 2019;54(Suppl 2):780–4.PubMedCrossRef
198.
Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545–53.PubMedPubMedCentralCrossRef
199.
Leaman Alcibar O, Candini D, López-Campos F, Albert Antequera M, Morillo Macías V, Conde AJ, et al. Time for radioimmunotherapy: an overview to bring improvements in clinical practice. Clin Transl Oncol. 2019;21(8):992–1004.PubMedCrossRef
200.
Modak S, Zanzonico P, Grkovski M, Slotkin EK, Carrasquillo JA, Lyashchenko SK, et al. B7H3-directed intraperitoneal radioimmunotherapy with radioiodinated omburtamab for desmoplastic small round cell tumor and other peritoneal tumors: results of a phase I study. J Clin Oncol. 2020;38(36):4283–91.PubMedPubMedCentralCrossRef
201.
Adams JL, Smothers J, Srinivasan R, Hoos A. Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov. 2015;14(9):603–22.PubMedCrossRef
202.
Berg WA, Bandos AI, Mendelson EB, Lehrer D, Jong RA, Pisano ED. Ultrasound as the primary screening test for breast cancer: analysis from ACRIN 6666. J Natl Cancer Inst. 2016;108(4):djv367.PubMedCrossRef
203.
Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, et al. Association of screening and treatment with breast cancer mortality by molecular subtype in US women, 2000–2012. JAMA. 2018;319(2):154–64.PubMedPubMedCentralCrossRef
204.
Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med. 1998;338(16):1089–96.PubMedCrossRef
205.
Bam R, Lown PS, Stern LA, Sharma K, Wilson KE, Bean GR, et al. Efficacy of affibody-based ultrasound molecular imaging of vascular B7–H3 for breast cancer detection. Clin Cancer Res. 2020;26(9):2140–50.PubMedPubMedCentralCrossRef
206.
Bachawal SV, Jensen KC, Wilson KE, Tian L, Lutz AM, Willmann JK. Breast cancer detection by B7-H3-targeted ultrasound molecular imaging. Cancer Res. 2015;75(12):2501–9.PubMedPubMedCentralCrossRef
207.
Wilson KE, Bachawal SV, Abou-Elkacem L, Jensen K, Machtaler S, Tian L, et al. Spectroscopic photoacoustic molecular imaging of breast cancer using a B7-H3-targeted ICG contrast agent. Theranostics. 2017;7(6):1463–76.PubMedPubMedCentralCrossRef
208.
Bam R, Laffey M, Nottberg K, Lown PS, Hackel BJ, Wilson KE. Affibody-indocyanine green based contrast agent for photoacoustic and fluorescence molecular imaging of B7–H3 expression in breast cancer. Bioconjug Chem. 2019;30(6):1677–89.PubMedPubMedCentralCrossRef
209.
Bachawal S, Bean GR, Krings G, Wilson KE. Evaluation of ductal carcinoma in situ grade via triple-modal molecular imaging of B7–H3 expression. NPJ Breast Cancer. 2020;6:14.PubMedPubMedCentralCrossRef
Metadata
Title
A promising target for breast cancer: B7-H3
Authors
Ying Jiang
Jiayu Liu
Lingyan Chen
Zhiwen Qian
Yan Zhang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-11933-3

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Discovery of a small molecule that inhibits Bcl-3-mediated cyclin D1 expression in melanoma cells

Retraction Note

Retraction Note: Curcumin inhibits proliferation, migration, invasion and promotes apoptosis of retinoblastoma cell lines through modulation of miR-99a and JAK/STAT pathway

Research

Epidemiology, characteristics, and prognostic factors of lymphoplasmacyte-rich meningioma: a systematic literature review

Correction

Correction: Prognostic value of pre-treatment [18F] FDG PET/CT in recurrent nasopharyngeal carcinoma without distant metastasis

Research

Desmoglein 2 and desmocollin 2 depletions promote malignancy through distinct mechanisms in triple-negative and luminal breast cancer

Research

Prognostic value of pre-treatment [18F] FDG PET/CT in recurrent nasopharyngeal carcinoma without distant metastasis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits